Metavia Inc Share Price

NASDAQ: MTVA

Mega Cap

$1.07

-0.26

(-19.55%)

as on September 18, 2025 at 1:29 am IST

$₹

Metavia Inc Stock Performance

as on September 18, 2025 at 1:29 am IST

Day's Low
Day's High
$1.06
Day's Price Range
$1.19
$1.07
0.93%
Downside
11.21%
Upside
52 Week's Low
52 Week's High
$0.56
52-Week Price Range
$2.75
$1.07
48.08%
Downside
157.01%
Upside

Metavia Inc share price movements today

Previous Close: $1.33
Open: $1.18
Volume: 1.2M
Day's Low - High: $1.06 - $1.19
52 Week Low - High: $0.56 - $2.75

Metavia Inc Historical Returns

1 Month Return: + 104.43 %
3 Month Return: + 90 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Metavia Inc Stock Fundamentals & Key Indicators

Check Metavia Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$14.4M

EPS (TTM)

Dividend Yield

0.00%

PE Ratio (TTM)

P/B Ratio

PEG Ratio

Return On Equity TTM

1335875200.00%

Metavia Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Metavia Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Metavia Inc	NA	$14.4M	NA	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$60.5B	248.74%	-505.15	-12.96%
Beone Medicines Ltd	NA	$38.7B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$99.3B	45.88%	27.56	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$60.9B	5.45%	14.49	31.37%

Metavia Inc Stock's Interest Amongst Investors

Search interest for Metavia Inc Stock has increased by 26% in the last 30 days, reflecting an upward trend in search activity.

Time period: August 19, 2025 to September 18, 2025

Change:26% versus previous 30 day period

Metavia Inc Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	-	-	-	-	-	-	-	-
Gross Profit	0	0	0	0	0	0	0	0
Operating Income	-3	-5	-6	-10	-6	-5	-3	-4
EBITDA	-3	-2	-6	-10	-6	-5	-3	-3
Interest Expense	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0
Income Before Tax	-3	-5	-6	-10	-5	-5	-3	-3
Income Tax Expense	-	-	-	-	-	-	-	-
Net Income	-3	-5	-6	-10	-5	-5	-3	-3
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Metavia Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	-	-	-	-
Gross Profit	0	0	0	0	0
Operating Income	-29	-15	-19	-15	-28
EBITDA	-29	-15	-11	-15	-28
Interest Expense	-	-	2	-	-
Depreciation	0	0	0	0	0
Income Before Tax	-29	-15	-13	-12	-27
Income Tax Expense	-	-	-	-	-
Net Income	-29	-15	-13	-12	-27
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%

Metavia Inc Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	0	-3	-5	-6	-10	-5	-5	-3	-3
Operating Cash Flow	-2	-2	-3	-6	-7	-5	-5	-4	-3
Investing Cash Flow	-	0	0	0	0	-	-	-	0
Financing Cash Flow	0	-	-	-	19	0	0	0	9
Change in Cash	-2	-2	-3	-6	11	-6	-5	-4	6

Metavia Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-14	-33	-15	-21	-29	-15	-13	-12	-27
Operating Cash Flow	-11	-26	-14	-7	-10	-15	-11	-10	-24
Investing Cash Flow	-	-	0	-6	0	0	0	0	0
Financing Cash Flow	31	21	17	24	6	22	28	0	18
Change in Cash	20	-5	2	11	-3	6	16	-10	-6

Insights on Metavia Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 7 days, MTVA stock has moved up by 55.0%
NO EFFECT
Against Peers
In the last 1 year, Beone Medicines Ltd has given 68.4% return, outperforming this stock by 137.2%
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 111.5% return, outperforming this stock by 210.8%

About Metavia Inc

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.

Organisation	Metavia Inc
Headquarters	545 Concord Avenue, Cambridge, MA, United States, 02138
CEO	Mr. Heon Kim Hyung
E-voting on shares	Click here to vote

Key Management of Metavia Inc

Name	Title
Mr. Heon Kim Hyung	CEO, President & Director
Mr. Marshall H. Woodworth	Chief Financial Officer
Dr. Mi-Kyung Kim	Chief Scientific Officer
Mr. Robert Homolka	Senior Vice President of Clinical Operations
Dr. W. Christopher Fang M.D.	Consulting Chief Medical Officer & Advisor
Mr. Michael Pine	Senior Vice President of Business Development Advisor

FAQs

What is Metavia Inc share price today?

Metavia Inc share price today is $1.07 as on September 18, 2025 at 1:29 am IST at the close of the market. Metavia Inc share today touched a day high of $1.19 and a low of $1.06.

What is the 52 week high and 52 week low for Metavia Inc share?

Metavia Inc share touched a 52 week high of $2.75 on January 6, 2025 and a 52 week low of $0.56 on August 4, 2025. Metavia Inc stock price today i.e. September 18, 2025 at 1:29 am IST is closed at $1.07,which is 61.09% down from its 52 week high and 92.62% up from its 52 week low.

What is Metavia Inc's market capitalisation today?

Metavia Inc market capitalisation is $0.00T as on September 18, 2025 at 1:29 am IST.

How to invest in Metavia Inc Stock (MTVA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Metavia Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Metavia Inc Shares that will get you 1.4019 shares as per Metavia Inc share price of $1.07 per share as on September 18, 2025 at 1:29 am IST.

What is the minimum amount required to buy Metavia Inc Stock (MTVA) from India?

Indian investors can start investing in Metavia Inc (MTVA) shares with as little as ₹87.816 or $1 (as of September 18, 2025 at 3:44 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹878.16 in Metavia Inc stock (as per the Rupee-Dollar exchange rate as on September 18, 2025 at 3:44 pm IST). Based on Metavia Inc share’s latest price of $1.07 as on September 18, 2025 at 1:29 am IST, you will get 9.3458 shares of Metavia Inc. Learn more about fractional shares .